Opinion: BC needs to step up and provide access to long-acting HIV medications

I have been living with HIV (Human Immunodeficiency Virus) for 38 years, and have had an undetectable viral load (less than 40 copies/mL) since 1998. Both of these facts are possible because of activism, community care, and HIV medications.

BC has been my home for 28 years. I chose to live here because this province, and the BC Centre for Excellence in HIV/AIDS (BC-CfE), has led the charge in HIV treatment innovation throughout the epidemic: the development of HIV triple-drug combination therapy called “highly active antiretroviral therapy” (HAART), and for developing the Treatment as Prevention® Strategy (TasP®), which has linked patients to care, treatment and prevention. Working together with numerous community organizations, the BC Centre for Excellence in HIV/AIDS has saved the lives of thousands of HIV-positive people and reduced new HIV infections.

Scroll to Top

The BC-CfE Laboratory is streamlining reporting processes for certain tests in order to simplify distribution and record-keeping, and to ensure completeness of results. Beginning September 2, 2025, results for the ‘Resistance Analysis of HIV-1 Protease and Reverse Transcriptase’ (Protease-RT) and ‘HIV-1 Integrase Resistance Genotype’ tests will be combined into a single ‘HIV-1 Resistance Genotype Report’.
For more details and example reports, please click on the button below